Potential for Using EGFR Expression in Rhabdomyosarcoma, Osteosarcoma and Ewing’s Sarcoma: Clinicopathological and Prognostic Significance

(Hassan Fouad Huwait, Hatim Qasim Almaghrabi, Mariana Fouad Gayyed and Hanan Mohamed Abd Elmoneim)

---

Abstract

Sarcomas are a heterogeneous group of malignant tumors that arise from mesenchymal cells and can arise anywhere in the body, whether it is soft tissue or bone. Epidermal growth factor receptor (EGFR) expression in pediatric sarcomas is explored in the current study. A key feature of EGFRs is their general involvement in signal transduction and oncogenesis, making them one of the most studied receptor protein-tyrosine kinase families. The study included 104 archived formalin-fixed paraffin-embedded blocks assessed using immunohistochemical stains for EGFR expression in rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. EGFR gene copy number was analyzed by dual silver in situ hybridization (DISH). EGFR was positively expressed in 56.7% of pediatric sarcoma. Immunostaining for EGFR was significantly associated with deep large tumors, stage, and histologic grade. Significantly, lower chances of overall survival were observed with elevated levels of EGFR five years post-diagnosis. EGFR staining identified independent risk factors for poor patient outcomes. The results of in situ hybridization did not indicate EGFR gene amplification in any of the cases assessed. EGFR overexpression was an independent predictor of pediatric sarcoma outcome, which is highly associated with histologic grade and stage. Results indicate EGFR inhibitors should be potentiated and directed against pediatric sarcoma.

KEYWORDS
EGFR, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma

PDF

References

Ålgars, A., Lintunen, M., Carpén, O., Ristamäki, R. and Sundström, J. (2011). EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J. Cancer, 105(2), 255–62. 
Aljuhani, W.S., Alanazi, A.M. and Alghafees, M.A. (2021). Primary bone sarcomas in KSA: A Saudi tumor registry review. Journal of Taibah University Medical Sciences, 16(1), 77–85.
Basbous, M., Al-Jadiry, M., Belgaumi, A., Sultan, I., Al-Haddad, A., Jeha, S. and Saab, R. (2021). Childhood cancer care in the Middle East, North Africa, and West/Central Asia: A snapshot across five countries from the POEM network. Cancer Epidemiol, 71(Pt B), 101727.
Birkman, E.M., Ålgars, A., Lintunen, M., Ristamäki, R., Sundström, J. and Carpén, O. (2016). EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. BMC Cancer, 16(1), 406–6.
Borgatti, A., Koopmeiners, J.S., Sarver, A.L., Winter, A.L., Stuebner, K., Todhunter, D., Rizzardi, A.E., Henriksen, J.C., Schmechel, S., Forster, C.L., Kim, J.-H., Froelich, J., Walz, J., Henson, M.S., Breen, M., Lindblad-Toh, K., Oh, F., Pilbeam, K., Modiano, J.F. and Vallera, D.A. (2017). Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Mol Cancer Ther, 16(5), 956–65.
Braun, A.C., de Mello, C.A.L., Corassa, M., Abdallah, E.A., Urvanegia, A.C., Alves, V.S., Flores, B., Díaz, M., Nicolau, U.R., Silva, V.S.E., Calsavara, V., Paterlini-Brechót, P. and Chinen, L.T.D. (2018). EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas. Cancer Biol Ther, 19(6), 454–60.
Capasso, M., Montella, A., Tirelli, M., Maiorino, T., Cantalupo, S. and Iolascon, A. (2020). Genetic predisposition to solid pediatric cancers. Frontiers in Oncology, 10(n/a), 590033.
Choi, J.H. and Ro, J.Y. (2021). The 2020 WHO classification of tumors of soft tissue: Selected changes and new entities. Adv Anat Pathol, 28(1), 44–58.
El Demellawy, D., McGowan-Jordan, J., de Nanassy, J., Chernetsova, E. and Nasr, A. (2017). Update on molecular findings in rhabdomyosarcoma. Pathology, 49(3), 238–46.
Gaiser, T., Waha, A., Moessler, F., Bruckner, T., Pietsch, T. and von Deimling, A. (2009). Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Modern Pathology, 22(9), 1263–71.
Ganti, R., Skapek, S.X., Zhang, J., Fuller, C.E., Wu, J., Billups, C.A., Breitfeld, P.P., Dalton, J.D., Meyer, W.H. and Khoury, J.D. (2006). Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol, 19(9), 1213–20.
Jagodzińska-Mucha, P., Raciborska, A., Koseła-Paterczyk, H., Kozak, K., Bilska, K., Świtaj, T., Falkowski, S., Dawidowska, A., Rutkowski, P. and Ługowska, I. (2021). Age as a prognostic factor in patients with ewing sarcoma-The Polish sarcoma group experience. Journal of Clinical Medicine, 10(16), 3627.
Ji, X. L. and He, M. (2019). Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma. Aging, 11(15), 5848–63.
Kager, L., Tamamyan, G. and Bielack, S. (2017). Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol, 13(4), 357–68.
Kaufman, N.E.M., Dhingra, S., Jois, S.D. and Vicente, M.d.G.H. (2021). Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules (Basel, Switzerland), 26(4), 1076.
Kersting, C., Packeisen, J., Leidinger, B., Brandt, B., von Wasielewski, R., Winkelmann, W., van Diest, P.J., Gosheger, G. and Buerger, H. (2006). Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol, 59(6), 585–90.
Kersting, N., Kunzler Souza, B., Araujo Vieira, I., Pereira Dos Santos, R., Brufatto Olguins, D., José Gregianin, L., Tesainer Brunetto, A., Lunardi Brunetto, A., Roesler, R., Brunetto de Farias, C. and Schwartsmann, G. (2018). Epidermal growth factor receptor regulation of ewing sarcoma cell function. Oncology, 94(6), 383–93.
Martin-Giacalone, B.A., Weinstein, P.A., Plon, S.E. and Lupo, P.J. (2021). Pediatric rhabdomyosarcoma: Epidemiology and genetic susceptibility. Journal of Clinical Medicine, 10(9), 2028. doi: 10.3390/jcm10092028.
Nadeem Abbas, M., Kausar, S., Wang, F., Zhao, Y. and Cui, H. (2019). Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for glioblastoma. Cells, 8(4), 350. DOI: 10.3390/cells8040350.
Oh, F., Todhunter, D., Taras, E., Vallera, D.A. and Borgatti, A. (2018). Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol, 10(n/a), 113–21.
Oyama, T., Okamoto, K., Nakamura, R., Tajiri, R., Ikeda, H., Ninomiya, I. and Ooi, A. (2015). Overexpression and gene amplification of both ERBB2 and EGFR in an esophageal squamous cell carcinoma revealed by fluorescence in situ hybridization, multiplex ligation-dependent probe amplification and immunohistochemistry. Pathology International, 65(11), 608–13.
Pilbeam, K., Wang, H., Taras, E., Bergerson, R.J., Ettestad, B., DeFor, T., Borgatti, A., Vallera, D.A. and Verneris, M.R. (2017). Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors. Oncotarget, 9(15), 11938–47.
Roskoski, R., Jr. (2019). Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res, 139(n/a), 395–411.
Rot, S., Taubert, H., Bache, M., Greither, T., Würl, P., Holzhausen, H.-J., Eckert, A.W., Vordermark, D., and Kappler, M. (2018). Low HIF-1α and low EGFR mRNA expression significantly associate with poor survival in soft tissue sarcoma patients; the proteins react differently. Int J Mol Sci, 19(12), 3842.
Rudzinski, E.R., Kelsey, A., Vokuhl, C., Linardic, C.M., Shipley, J., Hettmer, S., Koscielniak, E., Hawkins, D.S. and Bisogno, G. (2021). Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the children's oncology group, European pediatric soft tissue sarcoma study group, and the cooperative weichteilsarkom studiengruppe. Pediatr Blood Cancer, 68(3), e28798.
Salgado, C.M., Zin, A., Garrido, M., Kletskaya, I., DeVito, R., Reyes-Múgica, M., Bisogno, G., Donofrio, V. and Alaggio, R. (2020). Pediatric soft tissue tumors with BCOR ITD express EGFR but not OLIG2. Pediatr Dev Pathol, 23(6), 424–30.
Sato, O., Wada, T., Kawai, A., Yamaguchi, U., Makimoto, A., Kokai, Y., Yamashita, T., Chuman, H., Beppu, Y., Tani, Y. and Hasegawa, T. (2005). Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer, 103(9), 1881–90.
Shi, Z., Chen, J., Guo, X., Cheng, L., Guo, X. and Yu, T. (2018). In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 1. J Cancer Res Ther, 14(1), 18–23.
Steliarova-Foucher, E., Colombet, M., Ries, L.A.G., Moreno, F., Dolya, A., Bray, F., Hesseling, P., Shin, H.Y. and Stiller, C.A. (2017). International incidence of childhood cancer, 2001-10: a population-based registry study. The Lancet. Oncology, 18(6), 719–31.
Sunpaweravong, P., Sunpaweravong, S., Puttawibul, P., Mitarnun, W., Zeng, C., Barón, A.E., Franklin, W., Said, S. and Varella-Garcia, M. (2005). Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol, 131(2), 111–9.
Teng, H.W., Wang, H.W., Chen, W.M., Chao, T.C., Hsieh, Y.Y., Hsih, C.H., Tzeng, C.H., Chen, P.C. and Yen, C.C. (2011). Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol, 103(8), 773–81.
Thomas, R. and Weihua, Z. (2019). Rethink of EGFR in cancer with its kinase independent function on board. Frontiers in oncology, 9(n/a), 800.
Wang, X., Yeo, R.X., Hogg, P.J., Goldstein, D., Crowe, P., Dilda, P.J. and Yang, J.-L. (2020). The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. Oncotarget, 11(1), 46–61.
Yang, J.-L., Gupta, R.D., Goldstein, D. and Crowe, P.J. (2017). Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcoma. Int J Mol Sci, 18(6), 1159.
Yang, J.L., Hannan, M.T., Russell, P.J. and Crowe, P.J. (2006). Expression of HER1/EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol, 32(4), 466–8.
Yang, M., Zhang, T., Zhang, Y., Ma, X., Han, J., Zeng, K., Jiang, Y., Wang, Z., Wang, Z., Xu, J., Hua, Y., Cai, Z. and Sun, W. (2021). MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma. J Exp Clin Cancer Res, 40(1), 166.
Zöllner, S.K., Amatruda, J.F., Bauer, S., Collaud, S., de Álava, E., DuBois, S.G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., Shulman, D.S., Streitbürger, A., Timmermann, B., Toretsky, J.A., Uhlenbruch, Y., Vieth, V., Grünewald, T.G.P. and Dirksen, U. (2021). Ewing sarcoma- diagnosis, treatment, clinical challenges and future perspectives. Journal of Clinical Medicine, 10(8), 1685.